伊维菌素加速成人登革热患者NS1抗原清除的2/3期随机双盲安慰剂对照试验
该研究开展两项连续随机双盲安慰剂对照试验,评估伊维菌素在成人登革热患者中的安全性及病毒学和临床疗效。3天每日一次400 µg/kg口服伊维菌素安全且加速NS1清除,但该剂量下未观察到临床疗效。
要点
- 3天每日一次400 µg/kg伊维菌素可缩短登革热患者NS1抗原血症清除时间。
- 伊维菌素组出院时NS1不可测比例72.0%,高于安慰剂组47.6%。
- 该剂量下登革出血热发生率和不良事件与安慰剂无差异,临床疗效未显现。
核心结论
- 3天每日一次400 µg/kg口服伊维菌素安全,并加速成人登革热患者NS1抗原血症清除。
- 该剂量方案下未观察到伊维菌素的临床疗效。
研究设计与样本
- 两项连续随机双盲安慰剂对照试验,纳入成人登革热患者。
- 2期试验评估2天或3天每日一次400 µg/kg伊维菌素,3期试验评估3天每日一次400 µg/kg伊维菌素。
- 2期与3期合并意向治疗分析共203例,伊维菌素组100例、安慰剂组103例。
主要发现
- 两组病毒血症清除时间和不良事件发生率无差异。
关键数值与推荐
- 伊维菌素给药方案为400 µg/kg口服,每日一次,连续3天。
临床怎么用
- 该剂量伊维菌素可考虑用于加速登革热患者NS1抗原清除,但不应期望其改善临床结局。
- 临床决策需权衡抗病毒替代目的与缺乏临床疗效证据,不推荐常规用于改善登革热临床病程。
局限性
- 2期试验仅显示3天伊维菌素组NS1清除时间缩短的趋势。
- 该剂量方案下未观察到临床疗效。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dengue is the most significant mosquito-borne viral disease; there are no specific therapeutics. The antiparasitic drug ivermectin efficiently inhibits the replication of all 4 dengue virus serotypes in vitro. METHODS: We conducted 2 consecutive randomized, double-blind, placebo-controlled trials in adult dengue patients to evaluate safety and virological and clinical efficacies of ivermectin. After a phase 2 trial with 2 or 3 days of 1 daily dose of 400 µg/kg ivermectin, we continued with a phase 3, placebo-controlled trial with 3 days of 400 µg/kg ivermectin. RESULTS: The phase 2 trial showed a trend in reduction of plasma nonstructural protein 1 (NS1) clearance time in the 3-day ivermectin group compared with placebo. Combining phase 2 and 3 trials, 203 patients were included in the intention to treat analysis (100 and 103 patients receiving ivermectin and placebo, respectively). Dengue hemorrhagic fever occurred in 24 (24.0%) of ivermectin-treated patients and 32 (31.1%) patients receiving placebo (P = .260). The median (95% confidence interval [CI]) clearance time of NS1 antigenemia was shorter in the ivermectin group (71.5 [95% CI 59.9-84.0] hours vs 95.8 [95% CI 83.9-120.0] hours, P = .014). At discharge, 72.0% and 47.6% of patients in the ivermectin and placebo groups, respectively had undetectable plasma NS1 (P = .001). There were no differences in the viremia clearance time and incidence of adverse events between the 2 groups. CONCLUSIONS: A 3-day 1 daily dose of 400 µg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients. However, clinical efficacy of ivermectin was not observed at this dosage regimen.
引用
- Suputtamongkol Y, Avirutnan P, Mairiang D, et al. Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial. Clin Infect Dis. 2021. PMID: 33462580. doi:10.1093/cid/ciaa1332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。